Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and SurvivalDik J. Kwekkeboom, Eric P. Krenning, Wouter W. de Herder et al.|Journal of Clinical Oncology|2008Cited by 1.4k
Radiolabeled Somatostatin Analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsDik J. Kwekkeboom, Eric P. Krenning, Jaap J.M. Teunissen et al.|Journal of Clinical Oncology|2005Cited by 659
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsTessa Brabander, Dik J. Kwekkeboom, Wouter A. van der Zwan et al.|Clinical Cancer Research|2017Cited by 604
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation studyIrina Bancos, Ivana D. Pupovac, Tina Kienitz et al.|The Lancet Diabetes & Endocrinology|2020Cited by 247
Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paragangliaThomas Papathomas, Esther Korpershoek, Lindsey Oudijk et al.|Endocrine Related Cancer|2014Cited by 43